Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects

NCT01102972 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT01102972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01102972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects
Lead sponsor
ViiV Healthcare
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2010
Completion date
December 31, 2012
Enrollment
297 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

infection, human immunodeficiency virus